Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Nephrology

Long-Term Outlook and Staying on Track

At a Glance

For arterionephrosclerosis, long-term outlook depends more on trends in eGFR, UACR, and blood pressure than on a single lab result. Regular medication and potassium checks, plus heart-healthy habits, can help protect kidney function and reduce cardiovascular risk.

Arterionephrosclerosis is a chronic condition that requires a “marathon” mindset rather than a “sprint.” Because the damage happens slowly, the most important part of your care is consistent monitoring of three key markers: your blood pressure, your eGFR (filtering rate), and your UACR (urine protein level) [1][2].

Rather than focusing on a single lab result, your care team looks for trends over months and years [3]. While it is normal to feel “lab anxiety” before an appointment, remember that minor fluctuations are common and often do not change your long-term outlook [4].

Monitoring Your Medications

When you start or increase a kidney-protective medication like an ACE inhibitor or an ARB, your doctor will schedule blood tests—usually within 1 to 2 weeks—to check for two specific things [5]:

  1. The “Safe” eGFR Dip: It is very common for your eGFR to drop slightly (and your creatinine to rise) right after starting these drugs [4]. This happens because the medication is relaxing the pressure inside your kidney’s filters [6]. As long as the drop is less than 30%, it is generally considered a sign that the drug is working as intended to protect your kidneys long-term [4][5]. However, this dip is not a guarantee of safety. If the change is larger than 30%, or if you experience dehydration, urinary obstruction, or use NSAIDs, prompt clinical assessment is required. Do not assume any drop is safe without your doctor’s review.
  2. Potassium Levels: These medications can sometimes cause your body to hold onto too much potassium (hyperkalemia) [7]. If your levels rise, your doctor may suggest dietary changes or a “potassium binder” medication so you can stay on your kidney-protective blood pressure drugs safely [8].

Understanding Your Risk

To predict how your kidney disease might progress, doctors use two main pieces of information to “stratify” your risk:

  • eGFR (The Quantity of Function): A lower eGFR generally means a higher risk of progressing toward End-Stage Renal Disease (ESRD) [1].
  • UACR (The Quality of the Filter): The amount of protein (albumin) in your urine is often a more sensitive predictor of future damage than eGFR alone [1][9].

A patient with a stable eGFR and very little protein in their urine (UACR < 30 mg/g) typically has a much more favorable outlook, though risk depends on multiple factors, including age and the underlying cause [10]. Conversely, if protein levels are rising—for example, a fourfold increase—the risk of kidney failure increases significantly, regardless of what the eGFR says [11].

The Heart-Kidney Connection

One of the most important things to understand about “benign” nephrosclerosis is that it progresses very slowly [12]. In fact, many patients are statistically more likely to experience a cardiovascular event (like a heart attack or stroke) than they are to reach kidney failure [13].

This is because the same high blood pressure that damages the tiny vessels in your kidneys is also affecting the vessels in your heart and brain [14][15]. For this reason, managing your cholesterol, staying active, and blood pressure control are just as important for your “kidney” prognosis as your blood pressure meds [16]. Smoking cessation, physical activity tailored to your ability, and diabetes control are also vital. Do not start a daily aspirin for primary prevention on your own, as bleeding risks can outweigh benefits; aspirin is strictly for specific cardiovascular indications directed by a clinician [17].

Focusing on the Big Picture

It is easy to get lost in the numbers, but your “trend line” is what matters most. Using tools like the Kidney Failure Risk Equation (KFRE), your doctor can estimate your risk of needing dialysis over the next 2 to 5 years with high accuracy [18]. Keep in mind that the KFRE is principally validated for adults with established CKD (stages 3 to 5) and is an estimate rather than a guarantee. If your risk is low, you can find peace of mind in knowing that your current management plan is working, even if your kidney function isn’t “perfect” [19]. Organizing your results in a simple log or app can help you see these long-term trends and take the stress out of individual lab days.

Common questions in this guide

What do eGFR and UACR tell me about arterionephrosclerosis?
eGFR estimates how well your kidneys filter blood, while UACR measures albumin, a protein, in your urine. A lower eGFR or rising UACR generally signals higher risk, and changes over time are more useful than one isolated result.
Is a drop in eGFR after starting an ACE inhibitor or ARB dangerous?
A small eGFR decline and creatinine rise can occur soon after starting or increasing an ACE inhibitor or ARB because these medicines change pressure within the kidney filters. A decline of less than 30% is often considered an expected range, but your clinician must review the result; a larger change or dehydration, urinary blockage, or NSAID use needs prompt assessment.
How often should potassium be checked after a kidney-protective blood pressure medicine?
Blood tests are usually arranged within 1 to 2 weeks after starting or increasing an ACE inhibitor or ARB to check kidney function and potassium. The timing and potassium level that require a treatment change depend on your health and your clinician’s plan, so do not stop or adjust medicine on your own.
What does my UACR result mean for my future kidney health?
UACR measures albumin in urine, and a result below 30 mg/g is generally associated with a more favorable outlook when kidney function is stable. A rising or fourfold-increased UACR can signal higher risk even when eGFR has not changed, so compare results over time with your care team.
Can arterionephrosclerosis cause heart problems as well as kidney problems?
Yes. High blood pressure can damage blood vessels in the kidneys, heart, and brain, so cardiovascular events such as heart attack or stroke may be a greater concern than kidney failure for some people. Managing blood pressure, cholesterol, diabetes, smoking, and physical activity can help lower overall risk.
Can the Kidney Failure Risk Equation predict whether I will need dialysis?
The Kidney Failure Risk Equation estimates the chance of kidney failure or needing dialysis over the next 2 to 5 years using clinical information. It is mainly validated for adults with established chronic kidney disease at stages 3 to 5, and it estimates risk rather than guaranteeing what will happen.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my estimated risk using the Kidney Failure Risk Equation (KFRE), and am I in the right CKD stage for that tool to be accurate for me?
  2. 2.Since starting my blood pressure medication, how much did my eGFR change, and was the shift within a safe, expected range?
  3. 3.My latest UACR (albumin level) is [X]; how does this compare to my previous results, and does it change my overall risk category?
  4. 4.Given that cardiovascular health is tied to kidney health, are my cholesterol targets and lifestyle habits optimized to prevent a heart attack or stroke?
  5. 5.How often should I be getting blood tests to monitor my potassium levels, and what specific number would trigger a change in my treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility.

    James G, Garcia Sanchez JJ, Carrero JJ, et al.

    Kidney international reports 2022; (7(9)):2059-2070 doi:10.1016/j.ekir.2022.05.033.

    PMID: 36090504
  2. 2

    Chronic kidney disease in adults: assessment and management.

    Forbes A, Gallagher H

    Clinical medicine (London, England) 2020; (20(2)):128-132 doi:10.7861/clinmed.cg.20.2.

    PMID: 32165439
  3. 3

    The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts.

    Grams ME, Brunskill NJ, Ballew SH, et al.

    Journal of the American Society of Nephrology : JASN 2023; (34(3)):482-494 doi:10.1681/ASN.0000000000000050.

    PMID: 36857500
  4. 4

    Causal Effects of Renin-Angiotensin-Aldosterone System Inhibition on Renal Function in Patients With Chronic Kidney Disease: A Quasi-Experimental Study.

    Oh TR, Park J, Choi HS, et al.

    Clinical and translational science 2026; (19(4)):e70533 doi:10.1111/cts.70533.

    PMID: 41876398
  5. 5

    Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study.

    Schmidt M, Mansfield KE, Bhaskaran K, et al.

    BMJ open 2017; (7(1)):e012818 doi:10.1136/bmjopen-2016-012818.

    PMID: 28069618
  6. 6

    Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.

    Weir MR, Lakkis JI, Jaar B, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (72(6)):873-884 doi:10.1053/j.ajkd.2018.06.010.

    PMID: 30201547
  7. 7

    Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.

    Bandak G, Sang Y, Gasparini A, et al.

    Journal of the American Heart Association 2017; (6(7)) doi:10.1161/JAHA.116.005428.

    PMID: 28724651
  8. 8

    Novel Potassium Binders in Reduction of Hyperkalemia and Optimization of RAAS Inhibitors Treatment in Patients with Chronic Kidney Disease or Heart Failure: A Systematic Review and Meta-analysis.

    Huang N, Xu Y, Liu C, et al.

    Drugs 2025; (85(8)):1013-1031 doi:10.1007/s40265-025-02198-6.

    PMID: 40542996
  9. 9

    Cardiovascular and renal outcomes according to KDIGO stages of chronic kidney disease in the Spanish population: Insights from real-world evidence.

    Santamaria R, Escobar C, Aranda U, et al.

    Nefrologia 2025; (45(8)):501340 doi:10.1016/j.nefroe.2025.501340.

    PMID: 41173585
  10. 10

    Association of Albuminuria With Chronic Kidney Disease Progression in Persons With Chronic Kidney Disease and Normoalbuminuria : A Cohort Study.

    Verma A, Schmidt IM, Claudel S, et al.

    Annals of internal medicine 2024; (177(4)):467-475 doi:10.7326/M23-2814.

    PMID: 38560911
  11. 11

    Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality.

    Carrero JJ, Grams ME, Sang Y, et al.

    Kidney international 2017; (91(1)):244-251 doi:10.1016/j.kint.2016.09.037.

    PMID: 27927597
  12. 12

    Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign Nephrosclerosis.

    Sumida K, Hoshino J, Ueno T, et al.

    PloS one 2016; (11(1)):e0147690 doi:10.1371/journal.pone.0147690.

    PMID: 26809068
  13. 13

    Patients with biopsy-proven nephrosclerosis and moderately impaired renal function have a higher risk for cardiovascular disease: 15 years' experience in a single, kidney disease center.

    Suzuki H, Kobayashi K, Ishida Y, et al.

    Therapeutic advances in cardiovascular disease 2015; (9(3)):77-86 doi:10.1177/1753944715578596.

    PMID: 25838316
  14. 14

    Progression of Chronic Kidney Disease Risk Categories and Risk of Cardiovascular Disease and Total Mortality: Coronary Artery Risk Development in Young Adults Cohort.

    Choi Y, Jacobs DR, Shroff GR, et al.

    Journal of the American Heart Association 2022; (11(21)):e026685 doi:10.1161/JAHA.122.026685.

    PMID: 36314497
  15. 15

    Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.

    , Grams ME, Coresh J, et al.

    JAMA 2023; (330(13)):1266-1277 doi:10.1001/jama.2023.17002.

    PMID: 37787795
  16. 16

    Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets.

    Matsushita K, Jassal SK, Sang Y, et al.

    EClinicalMedicine 2020; (27()):100552 doi:10.1016/j.eclinm.2020.100552.

    PMID: 33150324
  17. 17

    Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP.

    Matsushita K, Kaptoge S, Hageman SHJ, et al.

    European journal of preventive cardiology 2023; (30(1)):8-16 doi:10.1093/eurjpc/zwac176.

    PMID: 35972749
  18. 18

    Validation of the Kidney Failure Risk Equation in Manitoba.

    Whitlock RH, Chartier M, Komenda P, et al.

    Canadian journal of kidney health and disease 2017; (4()):2054358117705372 doi:10.1177/2054358117705372.

    PMID: 28491341
  19. 19

    Performance of the Kidney Failure Risk Equation by Disease Etiology in Advanced CKD.

    Hundemer GL, Tangri N, Sood MM, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2020; (15(10)):1424-1432 doi:10.2215/CJN.03940320.

    PMID: 32928746

This page explains long-term monitoring and risk in arterionephrosclerosis for educational purposes only; it does not replace medical advice. Ask your clinician to interpret your eGFR, UACR, potassium results, and medication changes.

Get notified when new evidence is published on arterionephrosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.